#Annapolis #Atopic Dermatitis #Zabalafin Hydrogel #Alphyn Biologics

Alphyn Launches Phase 2b Clinical Trials for Atopic Dermatitis

Alphyn GmbH, a clinical-stage dermatology company, has officially kicked off its global Phase 2b clinical trial named CLEAR-AD1 to investigate the efficacy of Zabalafin Hydrogel in patients suffering from atopic dermatitis (AD). With the first doses already administered to eight patients in Australia, Alphyn aims to expand this trial to various sites across Europe and the United States by the end of the year.

Zabalafin Hydrogel represents a novel topical treatment targeting the underlying immunoinflammatory and bacterial causes of atopic dermatitis, from its onset to infection stages. The trial seeks to evaluate the safety, efficacy, and tolerability of Zabalafin Hydrogel specifically in patients with mild to moderate AD. This treatment is designed to be comprehensive, directly addressing itching and halting the immunoinflammatory cascade that exacerbates the disease.

A Unique Approach to Treatment

This clinical trial is particularly noteworthy because it is a randomized, double-blind, vehicle-controlled study. It encompasses two distinct stages of AD progression: one where bacteria contribute to the condition’s worsening without leading to infection, and another where bacterial involvement has escalated to the infection phase.